Latest Insider Transactions at Perrigo CO PLC (PRGO)
This section provides a real-time view of insider transactions for Perrigo CO PLC (PRGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PERRIGO Co plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PERRIGO Co plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2024
|
Adriana Karaboutis Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-15.76%
|
$126,210
$30.22 P/Share
|
|
May 15
2024
|
Adriana Karaboutis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+24.72%
|
$262,920
$30.22 P/Share
|
|
May 15
2024
|
Bradley A Alford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-10.46%
|
$126,210
$30.22 P/Share
|
|
May 15
2024
|
Bradley A Alford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+17.89%
|
$262,920
$30.22 P/Share
|
|
May 15
2024
|
Orlando D Ashford Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,259
-25.05%
|
$157,770
$30.22 P/Share
|
|
May 15
2024
|
Orlando D Ashford Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,955
+34.29%
|
$328,650
$30.22 P/Share
|
|
May 15
2024
|
Katherine C. Doyle Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-21.95%
|
$126,210
$30.22 P/Share
|
|
May 15
2024
|
Katherine C. Doyle Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+31.37%
|
$262,920
$30.22 P/Share
|
|
May 15
2024
|
Donal O'Connor Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-14.17%
|
$126,210
$30.22 P/Share
|
|
May 15
2024
|
Donal O'Connor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+22.79%
|
$262,920
$30.22 P/Share
|
|
May 15
2024
|
Geoffrey M. Parker Director |
SELL
Payment of exercise price or tax liability
|
Direct |
4,207
-17.19%
|
$126,210
$30.22 P/Share
|
|
May 15
2024
|
Geoffrey M. Parker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,764
+26.37%
|
$262,920
$30.22 P/Share
|
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,170
-5.26%
|
$33,930
$29.69 P/Share
|
|
Mar 07
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,249
+9.18%
|
$65,221
$29.69 P/Share
|
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,125
-3.45%
|
$32,625
$29.69 P/Share
|
|
Mar 07
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,163
+6.22%
|
$62,727
$29.69 P/Share
|
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
886
-2.57%
|
$25,694
$29.69 P/Share
|
|
Mar 07
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,942
+7.87%
|
$85,318
$29.69 P/Share
|
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
526
-2.84%
|
$15,254
$29.69 P/Share
|
|
Mar 07
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,746
+8.61%
|
$50,634
$29.69 P/Share
|
|
Mar 07
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
5,468
+5.14%
|
$158,572
$29.69 P/Share
|
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-4.38%
|
$25,620
$28.09 P/Share
|
|
Mar 06
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+7.76%
|
$49,252
$28.09 P/Share
|
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
915
-2.92%
|
$25,620
$28.09 P/Share
|
|
Mar 06
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,759
+5.31%
|
$49,252
$28.09 P/Share
|
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
693
-2.15%
|
$19,404
$28.09 P/Share
|
|
Mar 06
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,300
+6.67%
|
$64,400
$28.09 P/Share
|
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,147
-9.34%
|
$32,116
$28.09 P/Share
|
|
Mar 06
2024
|
Kyle Hanson EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
3,518
+22.26%
|
$98,504
$28.09 P/Share
|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
696
-6.11%
|
$19,488
$28.09 P/Share
|
|
Mar 06
2024
|
Thomas Farrington EVP and CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,881
+14.17%
|
$52,668
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,267
-9.53%
|
$35,476
$28.09 P/Share
|
|
Mar 06
2024
|
Eduardo Guarita Bezerra EVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,870
+26.81%
|
$136,360
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
612
-3.52%
|
$17,136
$28.09 P/Share
|
|
Mar 06
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,030
+10.45%
|
$56,840
$28.09 P/Share
|
|
Mar 06
2024
|
Svend Andersen EVP & President CHCI |
BUY
Exercise of conversion of derivative security
|
Direct |
3,788
+3.82%
|
$106,064
$28.09 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,262
-4.14%
|
$34,074
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
2,490
+13.38%
|
$67,230
$27.26 P/Share
|
|
Mar 05
2024
|
Alison Ives EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,698
+10.72%
|
$45,846
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,178
-6.71%
|
$112,806
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Grant, award, or other acquisition
|
Direct |
11,806
+26.09%
|
$318,762
$27.26 P/Share
|
|
Mar 05
2024
|
Ronald Craig Janish EVP, Gbl Ops & SC & CTO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,071
+8.51%
|
$55,917
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,458
-6.92%
|
$120,366
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
7,291
+17.93%
|
$196,857
$27.26 P/Share
|
|
Mar 05
2024
|
Robert Willis EVP & CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,279
+4.56%
|
$34,533
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,519
-12.48%
|
$149,013
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,028
+27.46%
|
$243,756
$27.26 P/Share
|
|
Mar 05
2024
|
Grainne Quinn EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,583
+9.19%
|
$42,741
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,660
-21.83%
|
$125,820
$27.26 P/Share
|
|
Mar 05
2024
|
Thomas Farrington EVP and CIO |
BUY
Grant, award, or other acquisition
|
Direct |
9,652
+41.62%
|
$260,604
$27.26 P/Share
|